Target-specific killing of tumor cells with antibody-drug conjugates (ADCs) is an elegant concept in the continued fight against cancer. However, despite more than 20 years of clinical development, only four ADC have reached market approval, while at least 50 clinical programs were terminated early. The high attrition rate of ADCs may, at least in part, be attributed to heterogeneity and instability of conventional technologies. At present, various (chemo)enzymatic approaches for site-specific and stable conjugation of toxic payloads are making their way to the clinic, thereby potentially providing ADCs with increased therapeutic window.
- Synaffix ADC technology enters the clinic as collaboration with ADC Therapeutics advances // https://t.co/ltMAe3Tcnn https://t.co/5VzSZ0LHRZ 5 days ago
- In San Francisco for JPM? Hear about how you can access our #ADC technology and go rapidly to the clinic // 11:45a… https://t.co/RGEhjLlA7S 2 weeks ago